EPISODE · Jun 28, 2008 · 18 MIN
What's so Great About TMC114?
from TheBody.com: Podcast Central
TheBody.com interviewed Dr. Cal Cohen, one of the lead researchers who investigated TMC114 (darunavir, Prezista) in clinical trials, to get his take on some of the key questions surrounding this new HIV medication: Why should we be so excited about TMC114? What side effects can it cause? How is it likely to change the way HIVers with multidrug resistance are treated?
Embed this episode
NOW PLAYING
What's so Great About TMC114?
0:00
18:19
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of TheBody.com: Podcast Central?
This episode is 18 minutes long.
When was this TheBody.com: Podcast Central episode published?
This episode was published on June 28, 2008.
Can I download this TheBody.com: Podcast Central episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!